Search
Close this search box.

An oncolytic virus–T cell chimera for cancer immunotherapy – Nature Biotechnology

  • Melcher, A., Harrington, K. & Vile, R. Oncolytic virotherapy as immunotherapy. Science 374, 1325–1326 (2021).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. Y. E., Bell, J. C. & Nelson, B. H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer 18, 419–432 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tian, Y., Xie, D. & Yang, L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct. Target. Ther. 7, 117 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Killock, D. T-VEC oncolytic viral therapy shows promise in melanoma. Nat. Rev. Clin. Oncol. 12, 438 (2015).

    Article 
    PubMed 

    Google Scholar
     

  • Andtbacka, R. H. I. et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 25 (2015).

    Article 

    Google Scholar
     

  • Breitbach, C. J. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477, 99–102 (2011).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Nemunaitis, J. et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746–759 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–567 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Carlisle, R. C. et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909–1918 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sampath, P. et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol. Ther. 21, 620–628 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lyons, M. et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. 14, 118–128 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Garcia-Carbonero, R. et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J. Immunother. Cancer 5, 71 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu, Z. et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Flies, D. B. & Chen, L. The new B7s: playing a pivotal role in tumor immunity. J. Immunother. 30, 251–260 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang, G. et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11, 1395 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lin, C. et al. Intratumoral delivery of a PD-1–blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade. Cancer Immunol. Res. 8, 632–647 (2020).


    Google Scholar
     

  • Cole, C. et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med. 11, 1073–1081 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Evgin, L. et al. Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci. Transl. Med. 14, eabn2231 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zheng, N. et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell 40, 973–985 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Villa, N. Y. et al. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 125, 3778–3788 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fares, J. et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1 clinical trial. Lancet Oncol. 22, 1103–1114 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jazowiecka-Rakus, J. et al. Myxoma virus-loaded mesenchymal stem cells in experimental oncolytic therapy of murine pulmonary melanoma. Mol. Ther. Oncolytics 18, 335–350 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lv, P. et al. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy. Nano Lett. 19, 2993–3001 (2019).

    Article 
    ADS 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen, J. et al. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy. ACS Nano 10, 11548–11560 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Aoyama, K. et al. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. Sci. Rep. 7, 14177 (2017).

    Article 
    CAS 

    Google Scholar
     

  • Keshavarz, M. et al. Oncolytic virus delivery modulated immune responses toward cancer therapy: challenges and perspectives. Int. Immunopharmacol. 108, 108882 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Atasheva, S. et al. Systemic cancer therapy with engineered adenovirus that evades innate immunity. Sci. Transl. Med. 12, eabc6659 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hao, M. et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci. Transl. Med. 12, eaaz6667 (2020).

  • Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746–756 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Clarke, S. R. et al. Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol. Cell Biol. 78, 110–117 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mulcahy, L. A., Pink, R. C. & Carter, D. R. F. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 3, 24641 (2014).

    Article 

    Google Scholar
     

  • Nath, S. C. et al. Fluid shear stress promotes embryonic stem cell pluripotency via interplay between β-catenin and vinculin in bioreactor culture. Stem Cells 39, 1166–1177 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mariuzza, R. A., Agnihotri, P. & Orban, J. The structural basis of T-cell receptor (TCR) activation: an enduring enigma. J. Biol. Chem. 295, 914–925 (2020).

    Article 
    PubMed 

    Google Scholar
     

  • Mardi, A. et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int. 22, 168 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hillerdal, V. et al. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice. BMC Cancer 14, 30 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang, S. et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci. Transl. Med. 13, eabb6981 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yi, J., Balagopalan, L., Nguyen, T., McIntire, K. M. & Samelson, L. E. TCR microclusters form spatially segregated domains and sequentially assemble in calcium-dependent kinetic steps. Nat. Commun. 10, 277 (2019).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 27, 1362 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • McLeod, H. L. et al. Assessment of adverse events and their ability to discriminate response to anti-PD-1/PD-L1 antibody immunotherapy. J. Clin. Oncol. 38, 103–104 (2020).

    Article 
    PubMed 

    Google Scholar
     

  • Burr, M. L. et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature 549, 101–105 (2017).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Doundna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Mattapally, S. et al. Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy. J. Am. Heart Assoc. 7, e010239 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).

  • Wang, Y. et al. Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. Nat. Commun. 14, 1993 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Badrinath, S. et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature 606, 992–998 (2022).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chen, Y. et al. An oncolytic virus-T-cell chimera for cancer immunotherapy. https://www.ncbi.nlm.nih.gov/sra/PRJNA939261